56041-75-9

Usage

Uses

Used in Organic Synthesis:
4-bromo-alpha-cyclopropyl-alpha-methylbenzyl alcohol is utilized as a building block or intermediate in the synthesis of various other chemicals. Its unique structure allows for the creation of a wide range of chemical compounds, making it a versatile component in organic chemistry.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 4-bromo-alpha-cyclopropyl-alpha-methylbenzyl alcohol is employed as a key intermediate in the production of pharmaceuticals. Its properties contribute to the development of new drugs, enhancing the range of treatments available for various medical conditions.
Used in Drug Development:
4-bromo-alpha-cyclopropyl-alpha-methylbenzyl alcohol's reactivity and structural features make it an important tool in drug development. It can be modified and combined with other molecules to create new pharmaceutical agents, potentially leading to breakthroughs in medicine.
Used in Chemical Research:
4-bromo-alpha-cyclopropyl-alpha-methylbenzyl alcohol is also used in chemical research to explore new reactions and mechanisms. Its unique properties provide researchers with opportunities to study and understand organic chemistry more deeply, potentially uncovering new pathways and applications for this and related compounds.

InChI:InChI=1/C11H13BrO/c1-11(13,8-2-3-8)9-4-6-10(12)7-5-9/h4-8,13H,2-3H2,1H3

Upstream product

• 765-43-5 Cyclopropyl methyl ketone 
• 18620-02-5 (4-bromophenyl)magnesium bromide 
• 6952-89-2 (4-bromophenyl)(cyclopropyl)methanone 
• 75-16-1 methylmagnesium bromide 
• 106-37-6 1.4-dibromobenzene 

Downstream Products

• 65322-32-9 1-bromo-4-(1-cyclopropylvinyl)benzene 
• 65322-29-4 1-(4-Bromo-phenyl)-2,2-dichloro-bicyclopropyl 
• 1360551-88-7 2-(4-bromo-phenyl)-2-cyclopropylpropionitrile 
• 1360552-61-9 2-{2-[4-(3-{(R)-1-[4-(2-amino-pyrimidin-5-yl)-phenyl]-1-cyclopropyl-ethyl}-[1,2,4]oxadiazol-5-yl)-pyrazol-1-yl]-ethyl}-isoindole-1,3-dione 
• 1360549-37-6 5-(4-{(R)-1-cyclopropyl-1-[5-(1H-pyrazol-4-yl)-[1,2,4]oxadiazol-3-yl]ethyl}phenyl)pyrimidin-2-ylamine 
• 1360550-04-4 2-[4-(3-{(1R)-1-[4-(2-aminopyrimidin-5-yl)phenyl]-1-cyclopropylethyl}-1,2,4-oxadiazol-5-yl)-1H-pyrazol-1-yl]-N,N-dimethylacetamide 
• 1360550-70-4 5-[4-((R)-1-cyclopropyl-1-{5-[1-(2-dimethylaminoethyl)-1H-pyrazol-4-yl]-[1,2,4]oxadiazol-3-yl}-ethyl)phenyl]pyrimidin-2-ylamine 
• 1360550-78-2 5-[4-((R)-1-{5-[1-(2-aminoethyl)-1H-pyrazol-4-yl]-[1,2,4]oxadiazol-3-yl}-1-cyclopropylethyl)phenyl]pyrimidin-2-ylamine 
• 1360551-91-2 (S)-2-(4-bromo-phenyl)-2-cyclopropylpropionitrile 
• 1360551-90-1 (R)-2-(4-bromo-phenyl)-2-cyclopropylpropionitrile 
• 1360552-09-5 (R,Z)-2-(4-(2-aminopyrimidin-5-yl)phenyl)-2-cyclopropyl-N′-hydroxypropanimidamide 
• 1360552-08-4 (R)-2-[4-(2-aminopyrimidin-5-yl)phenyl]-2-cyclopropylpropionitrile 
• 1360552-11-9 (R)-2-cyclopropyl-N-hydroxy-2-[4-(2-methylamino-pyrimidin-5-yl)-phenyl]-propionamidine 
• 1360552-10-8 C₁₇H₁₈N₄ 

Relevant academic research and scientific papers

Early Development Scale-Up of a Structurally-Challenging 5-Lipoxygenase Activating Protein (FLAP) Inhibitor

A practical and efficient synthesis of the FLAP inhibitor 1 was developed addressing multiple scale-up and safety concerns posed by the established synthesis and utilized a resolution strategy (replacing supercritical fluid chromatography (SFC) separation) for expedient access to the key structural component of 1: the challenging chiral quaternary center. Also highlighted are in situ IR monitoring, condensation to form the 1,2,4-oxadiazole ring, and an efficient Suzuki-Miyaura coupling.

HISTONE DEMETHYLASE INHIBITORS

The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like.

HETEROCYCLIC COMPOUNDS AS INHIBITORS OF LEUKOTRIENE PRODUCTION

The present invention relates to compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R1-R7, A and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes

OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION FOR COMBINATION THERAPY

The present invention relates to combination therapy using compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein and an additional pharmaceutically active agent. The invention also relates to pharmaceutical compositions comprising these combinations, and methods of using these combinations in the treatment of various diseases and disorders.

OXADIAZOLE INHIBITORS OF LEUKOTRIENE PRODUCTION

The present invention relates to compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.